http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2657419-C1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b94f5a4fed64e56a6fe26034a93b2cc0 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0043 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-186 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-137 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-38 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4174 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-30 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-38 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-137 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4174 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-18 |
| filingDate | 2017-03-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2018-06-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3adeb69f5c8ea77b6c22a109ecf17d57 |
| publicationDate | 2018-06-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2657419-C1 |
| titleOfInvention | Pharmaceutical composition for national administration |
| abstract | FIELD: medicine; pharmaceuticals. n SUBSTANCE: pharmaceutical composition for nasal administration comprises a complex of active components based on diphenhydramine hydrochloride, zinc sulfate and a water-soluble vasoconstrictor and a complex of auxiliary components comprising an isotonic agent, pH adjusting agent, a pharmaceutically acceptable gelling agent, a quaternary ammonium compound preservative and distilled water in the amounts indicated in the claims. As a vasoconstrictor, the composition comprises xylometazoline hydrochloride or phenylephrine hydrochloride. As a gelling agent, it contains carboxymethylcellulose or hydroxypropylmethylcellulose. As a preservative, the composition contains benzalkonium chloride or dodecyldimethylbenzylammonium chloride. As an isotonic agent, it contains sodium chloride or sodium hydrogencarbonate. As an agent regulating the pH of the aqueous phase, it contains sodium citrate, citric acid or sodium hydrochloride. n EFFECT: composition of the invention is characterized by high therapeutic efficacy and accelerates the epithelialization process of the nasal mucosa. n 8 cl, 4 ex |
| priorityDate | 2017-03-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 71.